These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 9614624

  • 1. Influence of interindividual variability of aldose reductase protein content on polyol-pathway metabolites and redox state in erythrocytes in diabetic patients.
    Hamada Y, Nishimura C, Koh N, Sakakibara F, Nakamura J, Tanimoto T, Hotta N.
    Diabetes Care; 1998 Jun; 21(6):1014-8. PubMed ID: 9614624
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. No correlation between glycemic control and an increase in erythrocyte aldose reductase activity in type I and type II diabetic patients.
    Hamada Y, Hammon K, Raskin P.
    J Diabetes Complications; 1992 Jun; 6(2):111-5. PubMed ID: 1611134
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Erythrocyte aldose reductase activity and sorbitol levels in diabetic retinopathy.
    Reddy GB, Satyanarayana A, Balakrishna N, Ayyagari R, Padma M, Viswanath K, Petrash JM.
    Mol Vis; 2008 Mar 24; 14():593-601. PubMed ID: 18385795
    [Abstract] [Full Text] [Related]

  • 7. High levels of erythrocyte aldose reductase and diabetic retinopathy in NIDDM patients.
    Nishimura C, Saito T, Ito T, Omori Y, Tanimoto T.
    Diabetologia; 1994 Mar 24; 37(3):328-30. PubMed ID: 8174849
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. In vitro retinal and erythrocyte polyol pathway regulation by hormones and an aldose reductase inhibitor.
    Hotta N, Kakuta H, Koh N, Fukasawa H, Yasuma T, Awaya S, Sakamoto N.
    Diabetes Res Clin Pract; 1991 Oct 24; 14(1):29-35. PubMed ID: 1748061
    [Abstract] [Full Text] [Related]

  • 10. Effects of an aldose reductase inhibitor on erythrocyte fructose 3-phosphate and sorbitol 3-phosphate levels in diabetic patients.
    Hamada Y, Odagaki Y, Sakakibara F, Naruse K, Koh N, Hotta N.
    Life Sci; 1995 Oct 24; 57(1):23-9. PubMed ID: 7596218
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Changes in erythrocyte sorbitol concentrations measured using an improved assay system in patients with diabetic complications and treated with aldose reductase inhibitor.
    Hayashi R, Hayakawa N, Makino M, Nagata M, Kakizawa H, Uchimura K, Hamada M, Aono T, Fujita T, Shinohara R, Nagasaka A, Itoh M.
    Diabetes Care; 1998 Apr 24; 21(4):672-3. PubMed ID: 9571366
    [No Abstract] [Full Text] [Related]

  • 14. Effect of aldose reductase inhibition on glutathione redox status in erythrocytes of diabetic patients.
    De Mattia G, Laurenti O, Bravi C, Ghiselli A, Iuliano L, Balsano F.
    Metabolism; 1994 Aug 24; 43(8):965-8. PubMed ID: 8052153
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Correlation between erythrocyte aldose reductase activity and the width of skeletal-muscle capillary basement membrane in insulin-dependent diabetes mellitus.
    Hamada Y, Hammon K, Raskin P.
    J Diabetes Complications; 1992 Aug 24; 6(4):242-6. PubMed ID: 1482782
    [Abstract] [Full Text] [Related]

  • 19. Increased erythrocyte aldose reductase activity in type 1 diabetic patients.
    Hamada Y, Kito R, Raskin P.
    Diabet Med; 1991 Apr 24; 8(3):226-31. PubMed ID: 1828737
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.